Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-labeled Anti-CEA Antibody Imaging in Rectal or Pancreatic Cancer
NCT06395337Phase 2Unknown
- Sponsor
- Radboud University Medical Center
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of indium-111 anti-CEA monoclonal antibody in rectal cancer, pancreatic ductal adenocarcinoma (PDAC), sponsored by Radboud University Medical Center. Status: unknown.
02
Drugs
indium-111 anti-CEA monoclonal antibody
03
Conditions
rectal cancerpancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06395337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395337.